Kenvue, Inc.: Hold Rating Amid FDA Concerns and Balanced Risks

Javier Escalante, an analyst from Evercore ISI, maintained the Hold rating on Kenvue, Inc.. The associated price target was lowered to $18.00.

Javier Escalante has given his Hold rating due to a combination of factors affecting Kenvue, Inc. The recent announcement by the FDA regarding potential safety label changes for acetaminophen, the active ingredient in Tylenol, poses significant headline and reputational risks for the company. This development could potentially alter consumer behavior, impacting sales of Tylenol, which is a major contributor to Kenvue’s revenue.
Additionally, while Tylenol commands a premium over private label alternatives, the news undermines its potential to expand as a global brand. Despite these challenges, Kenvue’s valuation is supported by its 5% dividend yield and potential efficiencies in selling, general, and administrative expenses. These factors collectively justify the Hold rating, as the risks and opportunities appear balanced at this time.

According to TipRanks, Escalante is a 2-star analyst with an average return of 0.6% and a 50.00% success rate. Escalante covers the Consumer Defensive sector, focusing on stocks such as Kimberly Clark, Clorox, and Kenvue, Inc..

In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $17.50 price target.